Patient characteristics
| Patient no. . | Age, y . | Sex . | Original diagnosis . | Prior therapies . | Prior responses . |
|---|---|---|---|---|---|
| 1 | 63 | F | PCNSL (DLBCL) | MT-R | CR (4 y) |
| Etoposide-cytarabine consolidation | CR (4 y) | ||||
| HD-MTX | PR | ||||
| WBRT | CR (1 yr) | ||||
| CyberKnife radiosurgery | PR | ||||
| 2 | 64 | F | PCNSL (DLBCL) | MT-R | PD (2 mo) |
| Etoposide-cytarabine | SD | ||||
| WBRT | CR (6 mo) | ||||
| 3 | 57 | F | Secondary CNSL (marginal zone) | R-CHOP | PR (systemic disease) |
| R-CVP | PR (systemic disease) | ||||
| HD-MTX | SD in CNS | ||||
| IT MTX | SD in CNS | ||||
| IT Ara-C | SD in CNS | ||||
| 4 | 61 | M | Secondary CNSL (DLBCL, testis) | R-CHOP, XRT | CR (systemic disease, 1 mo) |
| IT-MTX | PR in CNS | ||||
| IT-Ara-C | PR in CNS | ||||
| IT-DepoCyt | PR in CNS | ||||
| 5 | 55 | M | Secondary CNSL (DLBCL, skin) | R-CHOP, XRT | CR (systemic disease, 5 y) |
| HD-MTX, R | PD in CNS | ||||
| Etoposide-cytarabine | PD in CNS | ||||
| WBRT | PR in CNS | ||||
| 6 | 61 | M | Secondary CNSL (Burkitts) | R-CHOP followed by Zevalin | CR (systemic disease, 4 y) |
| R-hyper-CVAD, Velcade | PR, CNS progression | ||||
| R-ifosfamide, VP16, etoposide | CR (systemic disease) | ||||
| IT-MTX + IT-AraC | PR in CNS | ||||
| WBRT | CR (CNS, 6 mo) | ||||
| R-TMZ | PR in CNS | ||||
| IT-Topotecan | PR in CNS | ||||
| 7 | 75 | M | Secondary CNSL (DLBCL, testis) | R-CHOP, XRT | CR (systemic disease) |
| IT MTX | PR | ||||
| HD-MTX, R | PR | ||||
| 8 | 65 | M | PCNSL (DLBCL) | HD-MTX (complicated by renal failure) | SD in CNS |
| Pemetrexed | PD | ||||
| 9 | 37 | M | PCNSL (DLBCL) | HD-MTX, procarbazine, vincristine, rituximab (R-MPV) | PR |
| HD-Ara-C | PR | ||||
| IT-Ara-C | PR | ||||
| WBRT | PR | ||||
| IT-Ara-C | PR | ||||
| 10 | 59 | F | Secondary CNSL (DLBCL, sinus) | R-CHOP, XRT | CR |
| IT-MTX | PD in CNS | ||||
| MT-R | CR in CNS | ||||
| Etoposide-cytarabine | CR (1 mo) | ||||
| 11 | 58 | F | PCNSL (DLBCL) | MT-R | CR |
| Etoposide-cytarabine | CR (3 y) | ||||
| XRT | CR | ||||
| 12 | 64 | M | Secondary CNSL (DLBCL, sinus) | R-CHOP | CR (4 mo) |
| HD-MTX + IT MTX, + IT-Ara-C + IT HC | PD | ||||
| R-DHAP | PR | ||||
| IT-DepoCyt | PR | ||||
| MT-R | SD | ||||
| IV rituximab | SD | ||||
| 13 | 65 | F | PCNSL (DLBCL) | MT-R | CR |
| Etoposide-cytarabine consolidation | CR (2 y) | ||||
| HD-MTX, R | PR | ||||
| XRT | PR | ||||
| 14 | 51 | F | Secondary CNSL (transformed follicular) | R-CHOP | CR (1 mo) |
| IT-MTX (prophylaxis) | |||||
| HD-MTX, HD-Ara-C, R | PR | ||||
| R-DHAP + IT-MTX | PR | ||||
| Cy, BCNU, VP16 (CBV-based ASCT) | CR (2 mo) |
| Patient no. . | Age, y . | Sex . | Original diagnosis . | Prior therapies . | Prior responses . |
|---|---|---|---|---|---|
| 1 | 63 | F | PCNSL (DLBCL) | MT-R | CR (4 y) |
| Etoposide-cytarabine consolidation | CR (4 y) | ||||
| HD-MTX | PR | ||||
| WBRT | CR (1 yr) | ||||
| CyberKnife radiosurgery | PR | ||||
| 2 | 64 | F | PCNSL (DLBCL) | MT-R | PD (2 mo) |
| Etoposide-cytarabine | SD | ||||
| WBRT | CR (6 mo) | ||||
| 3 | 57 | F | Secondary CNSL (marginal zone) | R-CHOP | PR (systemic disease) |
| R-CVP | PR (systemic disease) | ||||
| HD-MTX | SD in CNS | ||||
| IT MTX | SD in CNS | ||||
| IT Ara-C | SD in CNS | ||||
| 4 | 61 | M | Secondary CNSL (DLBCL, testis) | R-CHOP, XRT | CR (systemic disease, 1 mo) |
| IT-MTX | PR in CNS | ||||
| IT-Ara-C | PR in CNS | ||||
| IT-DepoCyt | PR in CNS | ||||
| 5 | 55 | M | Secondary CNSL (DLBCL, skin) | R-CHOP, XRT | CR (systemic disease, 5 y) |
| HD-MTX, R | PD in CNS | ||||
| Etoposide-cytarabine | PD in CNS | ||||
| WBRT | PR in CNS | ||||
| 6 | 61 | M | Secondary CNSL (Burkitts) | R-CHOP followed by Zevalin | CR (systemic disease, 4 y) |
| R-hyper-CVAD, Velcade | PR, CNS progression | ||||
| R-ifosfamide, VP16, etoposide | CR (systemic disease) | ||||
| IT-MTX + IT-AraC | PR in CNS | ||||
| WBRT | CR (CNS, 6 mo) | ||||
| R-TMZ | PR in CNS | ||||
| IT-Topotecan | PR in CNS | ||||
| 7 | 75 | M | Secondary CNSL (DLBCL, testis) | R-CHOP, XRT | CR (systemic disease) |
| IT MTX | PR | ||||
| HD-MTX, R | PR | ||||
| 8 | 65 | M | PCNSL (DLBCL) | HD-MTX (complicated by renal failure) | SD in CNS |
| Pemetrexed | PD | ||||
| 9 | 37 | M | PCNSL (DLBCL) | HD-MTX, procarbazine, vincristine, rituximab (R-MPV) | PR |
| HD-Ara-C | PR | ||||
| IT-Ara-C | PR | ||||
| WBRT | PR | ||||
| IT-Ara-C | PR | ||||
| 10 | 59 | F | Secondary CNSL (DLBCL, sinus) | R-CHOP, XRT | CR |
| IT-MTX | PD in CNS | ||||
| MT-R | CR in CNS | ||||
| Etoposide-cytarabine | CR (1 mo) | ||||
| 11 | 58 | F | PCNSL (DLBCL) | MT-R | CR |
| Etoposide-cytarabine | CR (3 y) | ||||
| XRT | CR | ||||
| 12 | 64 | M | Secondary CNSL (DLBCL, sinus) | R-CHOP | CR (4 mo) |
| HD-MTX + IT MTX, + IT-Ara-C + IT HC | PD | ||||
| R-DHAP | PR | ||||
| IT-DepoCyt | PR | ||||
| MT-R | SD | ||||
| IV rituximab | SD | ||||
| 13 | 65 | F | PCNSL (DLBCL) | MT-R | CR |
| Etoposide-cytarabine consolidation | CR (2 y) | ||||
| HD-MTX, R | PR | ||||
| XRT | PR | ||||
| 14 | 51 | F | Secondary CNSL (transformed follicular) | R-CHOP | CR (1 mo) |
| IT-MTX (prophylaxis) | |||||
| HD-MTX, HD-Ara-C, R | PR | ||||
| R-DHAP + IT-MTX | PR | ||||
| Cy, BCNU, VP16 (CBV-based ASCT) | CR (2 mo) |
MT-R indicates high-dose MTX (HD-MTX), temozolomide, and rituximab; PCNSL, primary CNS lymphoma; DLBCL, diffuse large B-cell lymphoma; TMZ, temozolomide; R, rituximab; Ara-C, cytarabine; XRT, irradiation; WBXRT, whole-brain irradiation; IT, intrathecal; HC, hydrocortisone; DHAP (HD-Ara-C, cisplatin, and dexamethasone); hyper-CVAD, cyclophosphamide, vincristine, doxorubicin, dexamethasone, cytarabine, and methotrexate; BCNU, carmustine; SD, stable disease; and PD, progressive disease.